Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia

Combination therapy is one method of overcoming the global challenge of drug-resistant Plasmodium falciparum malaria. We conducted a hospital-based 28-day in vivo test comparing chloroquine/doxycycline to chlo- roquine or doxycycline alone for treating P. falciparum and Plasmodium vivax malaria in Irian Jaya, Indonesia. Eighty-nine patients with uncomplicated falciparum malaria were randomized to standard dose chloroquine (n 30), doxycycline (100 mg every 12 hours (7 days), n 20), or chloroquine with doxycycline (n 39); corresponding numbers for vivax malaria (n 63) were 23, 16, 24. Endpoints were parasite sensitivity (S) or resistance (RI/RII/ RIII). Of the 105 evaluable patients, chloroquine/doxycycline cured (S) 20/22 (90.9% (95% CI 78.9-100%)) patients with P. falciparum malaria; 2/22 (9.1% (0-21%)) were RIII resistant. Doxycycline cured 11/17 (64.7% (42.0-87.4%)) patients, and chloroquine 4/20 (20% (2.5-37.5%)). Against P. vivax, chloroquine/doxycycline cured (S) 12/17 (70.6% (48.9-92.2%)) patients, doxycycline 4/12 (33.3% (6.6-59.9%)), and chloroquine 5/17 (29.4% (7.7-51.1%)). Chloroquine/doxycycline was effective against P. falciparum but only modestly effective against P. vivax. These findings support the use of chloroquine/doxycycline as an inexpensive alternative to mefloquine for treating chloro- quine-resistant P. falciparum but not chloroquine-resistant P. vivax in this setting.